Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Diabetic Neuropathy influences the peripheral and central nervous integration of the nociceptive withdrawal reflex

    Publikation: KonferencebidragKonferenceabstrakt til konferenceForskningpeer review

  2. Thalamic atrophy is associated to intra-thalamic metabolites in type 1 diabetes with severe distal symmetrical polyneuropathy

    Publikation: KonferencebidragKonferenceabstrakt til konferenceForskningpeer review

  3. Mismatch 'never events' in hip and knee arthroplasty: a cohort and intervention study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Pathophysiology and management of diabetic gastroenteropathy

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

BACKGROUND: The β-lactam antibiotic piperacillin (in combination with tazobactam) is commonly chosen for empirical treatment of suspected bacterial infections. However, pharmacokinetic variability among patient populations and across ages leads to uncertainty when selecting a dosing regimen to achieve an appropriate pharmacodynamic target.

OBJECTIVES: To guide dosing by establishing a population pharmacokinetic model for unbound piperacillin in febrile children receiving cancer chemotherapy, and to assess pharmacokinetic/pharmacodynamic target attainment (100% fT > 1×MIC and 50% fT > 4×MIC) and resultant exposure, across body weights.

METHODS: Forty-three children admitted for 89 febrile episodes contributed 482 samples to the pharmacokinetic analysis. The typical doses required for target attainment were compared for various dosing regimens, in particular prolonged infusions, across MICs and body weights.

RESULTS: A two-compartment model with inter-fever-episode variability in CL, and body weight included through allometry, described the data. A high CL of 15.4 L/h (70 kg) combined with high glomerular filtration rate (GFR) values indicated rapid elimination and hyperfiltration. The target of 50% fT > 4×MIC was achieved for an MIC of 4.0 mg/L in a typical patient with extended infusions of 2-3 (q6h) or 3-4 (q8h) h, at or below the standard adult dose (75 and 100 mg/kg/dose for q6h and q8h, respectively). Higher doses or continuous infusion were needed to achieve 100% fT > 1×MIC due to the rapid piperacillin elimination.

CONCLUSIONS: The licensed dose for children with febrile neutropenia (80 mg/kg q6h as a 30 min infusion) performs poorly for attainment of fT>MIC pharmacokinetic/pharmacodynamic targets. Given the population pharmacokinetic profile, feasible dosing regimens with reasonable exposure are continuous infusion (100% fT > 1×MIC) or prolonged infusions (50% fT > 4×MIC).

TidsskriftThe Journal of antimicrobial chemotherapy
Udgave nummer10
Sider (fra-til)2984-2993
Antal sider10
StatusUdgivet - 1 okt. 2019
Eksternt udgivetJa

Bibliografisk note

© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email:

ID: 58441169